Wire · opportunities
Bubs Australia Wins Permanent FDA Approval For US Formula
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 September 2026 · Fusion42 review
Bubs Australia has received permanent approval from the US Food and Drug Administration (FDA) to sell three infant formula products in the US, enabling more stable market access and prompting the company to consider US private-label manufacturing to increase steady orders.
This Wire brief sits within Fusion42's coverage of Foodtech.
◆ ◆ The Wire takeaway
Permanent US FDA approval unlocks predictable access to the US infant formula market for you, shifting focus from market entry to scaling consistent supply and operations. Consider prioritising private-label deals to boost volumes and steady production despite slimmer margins.
◆ Coverage
1 source · 7 Sep 2026
◆ Related on Wire
◆ Topics